Refractory Large B-cell Lymphoma Clinical Trials

9 recruitingLast updated: June 18, 2026

There are 9 actively recruiting refractory large b-cell lymphoma clinical trials across 4 countries. Studies span Phase 2, Phase 1, Early Phase 1, Phase 3. Top locations include Tianjin, Tianjin Municipality, China, Boston, Massachusetts, United States, Camperdown, New South Wales, Australia. Updated daily from ClinicalTrials.gov.


Refractory Large B-cell Lymphoma Trials at a Glance

9 actively recruiting trials for refractory large b-cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Tianjin, Boston, and Camperdown. Lead sponsors running refractory large b-cell lymphoma studies include Institute of Hematology & Blood Diseases Hospital, China, Kite, A Gilead Company, and Curocell Inc..

Browse refractory large b-cell lymphoma trials by phase

Treatments under study

About Refractory Large B-cell Lymphoma Clinical Trials

Looking for clinical trials for Refractory Large B-cell Lymphoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Large B-cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Large B-cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 3

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

Relapsed or Refractory Large B-cell Lymphoma
Kite, A Gilead Company550 enrolled2 locationsNCT07479797
Recruiting
Early Phase 1

A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.

Relapsed/Refractory Large B-Cell Lymphoma
Shenzhen Fosun Kairos Biotechnology Co., Ltd.12 enrolled6 locationsNCT07606937
Recruiting
Phase 2

Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)

Relapsed or Refractory Large B-cell Lymphoma
University of Utah29 enrolled1 locationNCT06788964
Recruiting
Phase 1Phase 2

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Diffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)Relapsed Large B-cell Lymphoma+3 more
TICAROS Co., Ltd.98 enrolled1 locationNCT07473167
Recruiting
Phase 2

Outpatient Epcoritamab as 2L in NTE R/R DLBCL

Relapsed Large B-cell LymphomaRefractory Large B-cell Lymphoma
Massachusetts General Hospital30 enrolled2 locationsNCT06811272
Recruiting
Phase 1Phase 2

A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma

Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.112 enrolled15 locationsNCT05800977
Recruiting
Phase 2

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Relapsed/Refractory Large B-Cell Lymphoma
Peter MacCallum Cancer Centre, Australia40 enrolled6 locationsNCT06414148
Recruiting
Phase 2

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Relapsed/Refractory Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China89 enrolled1 locationNCT06489808
Recruiting
Phase 1Phase 2

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients

High-grade B-cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL)Primary Mediastinal Large B-cell Lymphoma (PMBCL)+3 more
Curocell Inc.91 enrolled1 locationNCT04836507